A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Active, not recruiting · Phase 1 · NCT05307705
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 17
- Sites paid
- 16
- Planned or actual enrollment
- 260
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LOXO-783 (drug), Fulvestrant (drug), Imlunestrant (drug), Abemaciclib (drug), Anastrozole, Exemestane, or Letrozole (drug), Paclitaxel (drug)
- Dates
- Started 2022-05-11; completion 2026-12
- Results posted
- Not yet
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.1M in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lida A. Mina, M.D Hematology & Oncology · Gilbert, AZ
- Nicholas Mcandrew, M.D. Hematology & Oncology · Los Angeles, CA
- Fauzia Riaz, MD Medical Oncology · Stanford, CA
- Hope S. Rugo, MD Hematology · San Francisco, CA
- Saranya Chumsri, MD Hematology & Oncology · Jacksonville, FL
- Manali A. Bhave, MD Medical Oncology · Chicago, IL
- Antonio Giordano, M.D., PH.D Medical Oncology · Boston, MA
- Dejan Juric, M.D. Medical Oncology · Boston, MA
- Matthew P. Goetz, M.D. Medical Oncology · Rochester, MN
- Cynthia X. Ma, MD Medical Oncology · Saint Louis, MO
- Komal Jhaveri Medical Oncology · New York, NY
- Ruth M. O'regan, MD Medical Oncology · Rochester, NY
- Erika P. Hamilton, M.D. Hematology & Oncology · Nashville, TN
- Muralidhar Beeram, M.D. Medical Oncology · San Antonio, TX
- Funda Meric, M.D. General Surgery · Houston, TX
- Joyce A. O'shaughnessy, MD Medical Oncology · Dallas, TX
- Nisha Unni, M.D. Hematology & Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $240,962
- Memorial Sloan-Kettering $190,585
- Mayo Clinic $188,883
- The University of Texas $109,045
- Sarah Cannon Research Institute LLC $90,378
- Dana Farber PArtners Cancer Care Inc $66,225
- Ronald Reagan UCLA Medical Center, CA $59,714
- Board of Trustees of the Leland Stanford Jr Univ $48,483
- Emory University Hospital, GA $35,931
- Strong Memorial Hospital, NY $28,962
- Texas Oncology PA $21,291
- South Texas Accelerated Research Therapeutics LLC $18,166
- Mayo Clinic Jacksonville $7,565
- Ut MD Anderson Cancer Center $5,379
- Mayo Clinic Hospital, AZ $4,710
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $2,817
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.